Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 498.

https://doi.org/10.1182/blood-2024-193738

Published: 2024

Journal Articles

Population Pharmacokinetics/Pharmacodynamics and Clinical Pharmacology of Zaltenibart (OMS906) in Healthy Subjects and Patients with PNH

W. Jason Cummings, Yi Li, Siobhan Hayes, Richard Mills, Colm Farrell, Morag Griffin, J. Steve Whitaker, William Pullman

Blood (2024) 144 (Supplement 1): 4081.

https://doi.org/10.1182/blood-2024-206009

Published: 2024

Journal Articles

Selinexor Combined with Daratumumab, Thalidomide, and Dexamethasone in Patients with First Relapsed Multiple Myeloma: A Single-Arm, Multicenter, Prospective Study

Qingxiao Chen, Jiasheng Wang, Yang Yang, Gaofeng Zheng, Jing Chen, Xiaoyan Han, Li Yang, Wenjun Wu, YI LI, Donghua He, Jingsong He, Zhen Cai

Blood (2024) 144 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2024-197887

Published: 2024

Journal Articles

Bruton's Tyrosine Kinase (BTK) Inhibitors Plus RM (rituximab and methotrexate) for the First-Line Treatment of Primary Central Nervous System Lymphoma (PCNSL)

Fangshu Guan, Xing Guo, Yi Li, Jing Chen, Jingsong He, Wenjun Wu, Zhen Cai, Yi Zhao

Blood (2024) 144 (Supplement 1): 6534.

https://doi.org/10.1182/blood-2024-212369

Published: 2024

Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study

Enrique M Ocio, Aurore Perrot, Pierre Bories, Jesús F. San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Song-Yau Wang, Sara Bringhen, Maria-Victoria Mateos, Paula Rodríguez-Otero, Stefania Oliva, Axel Nogai, Bruno Paiva, Yi Li, Eric Le Bras, Sandrine Macé, Ercem Kodas, Helgi Van de Velde, Philippe Moreau

Blood (2024) 144 (Supplement 1): 1976.

https://doi.org/10.1182/blood-2024-200135

Published: 2024

Journal Articles

Increase of Dnts Correlated with Clinic Outcome after Allogeneic DNT Cells Infusion in r/r AML Patients

Huiyao Gu, Donghua He, Xiaofeng Han, Yi Li, Li Yang, Enfan Zhang, Haicun Xie, Yu Cheng, Fuqiang Wu, Guangrong Song, Daqing Liu, Liming Yang, Jingsong He, Zhen Cai

Blood (2023) 142 (Supplement 1): 6867.

https://doi.org/10.1182/blood-2023-186221

Published: 2023

Journal Articles

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Xincheng Jiang, Zhen Cai, Xiaoyan Han, Fengyan Jin, Gang An, Jian Hou, Jingsong He, Qingming Wang, Wenjun Wu, Yi Zhao, Songfu Jiang, Shuchan Li, Zhenshu Xu, Gaofeng Zheng, Yang Yang, Qingxiao Chen, Donghua He, Yi Li

Blood (2023) 142 (Supplement 1): 6673.

https://doi.org/10.1182/blood-2023-174224

Published: 2023

Journal Articles

A Prospective Phase II Clinical Study of Low-Frequency Daratumumab for the Treatment of Systemic Light Chain Amyloidosis

Donghua He, Xinyi Meng, Jingsong He, Wenjun Wu, Jinuo Wang, Chunting Zhu, Xiaoyan Han, Yi Zhao, Gaofeng Zheng, Yi Li, Xing Guo, Qingxiao Chen, Fangshu Guan, Zhen Cai

Blood (2023) 142 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2023-184689

Published: 2023

Journal Articles

Alternative Pathway Masp-3 Inhibitor OMS906 Effectively and Potently Inhibits Complement-Mediated Hemolysis in Preclinical Models Mechanistically Similar to Paroxysmal Nocturnal Hemoglobinuria

Yi Li, Munehisa Yabuki, W. Jason Cummings

Blood (2023) 142 (Supplement 1): 4082.

https://doi.org/10.1182/blood-2023-177730

Published: 2023

Journal Articles

The Efficacy of Roxadustat in Multiple Myeloma Patients with Renal Insufficiency and Anemia: A Real-World Study

Shuchan Li, Xiaoyan Han, Gaofeng Zheng, Jingsong He, Wenjun Wu, Yang Yang, Qingxiao Chen, Donghua He, Mengmeng Dong, Jinuo Wang, Yi Li, Li Yang, Zhen Cai

Blood (2023) 142 (Supplement 1): 4726.

https://doi.org/10.1182/blood-2023-184617

Published: 2023

Journal Articles

Real-World Clinical Outcomes of Pomalidomide-Based and Daratumumab-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Cohort Study

Xiaoyan Han, Xincheng Jiang, Jingsong He, Gaofeng Zheng, Yaqin Xiong, Yanling Wen, Yang Yang, Donghua He, Qingxiao Chen, Wenjun Wu, Yi Zhao, Yi Li, Zhen Cai

Blood (2023) 142 (Supplement 1): 6639.

https://doi.org/10.1182/blood-2023-184794

Published: 2023

Journal Articles

Serum Ferritin Increased the Predictive Value of the International Staging System/Revised International Staging System for Overall Survival

Mengmeng Dong, Jinna Zhang, Li Yang, YI LI, Yang Yang, He Huang, Jingsong He, Zhen Cai

Blood (2022) 140 (Supplement 1): 12523.

https://doi.org/10.1182/blood-2022-156742

Published: 2022

Journal Articles

Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma

XiaoYan Yue, GaoFeng Zheng, Donghua He, Yang Yang, Xiaoyan Han, Yi LI, Yi Zhao, Qingxiao Chen, WenJun Wu, He Huang, Zhen Cai, Jingsong He

Blood (2022) 140 (Supplement 1): 7197.

https://doi.org/10.1182/blood-2022-159859

Published: 2022

Journal Articles

ALKBH5 Functions As an Oncogene in Multiple Myeloma

Jianwei Qu, Yifan Hou, Qingxiao Chen, Jing Chen, YI LI, Enfan Zhang, Huiyao Gu, Ruyi Xu, Yang Liu, Jingsong He, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 3326.

https://doi.org/10.1182/blood-2021-149622

Published: 2021

Journal Articles

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Yi Li, Jingsong He, Xiaoyan Han, Gaofeng Zheng, Enfan Zhang, Qingxiao Chen, Donghua He, Yi Zhao, Jiaping Fu, Lihong Shou, Wenhua Jiang, Wei Jiang, Shenxian Qian, Huixian Hu, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2021-149188

Published: 2021

Journal Articles

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Yongxian Hu, MD, Yali Zhou, Mingming Zhang, MD, Wengang Ge, Yi Li, MD, Li Yang, MD, Guoqing Wei, MD, Lu Han, Hao Wang, Xingwang Zhang, PhD, Jiangtao Ren, PhD, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 52.

https://doi.org/10.1182/blood-2020-142262

Published: 2020

Journal Articles

CCL2 Promotes Macrophages-Associated Chemoresistance Via MCPIP1 Dual Catalytic Activities in Multiple Myeloma

Ruyi Xu, Yi Li, MD, Haimeng Yan, MD, Xi Huang, MD, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2019) 134 (Supplement_1): 3086.

https://doi.org/10.1182/blood-2019-126498

Published: 2019

Journal Articles

The Novel Subtype-Selective Histone Deacetylase (HDAC) Inhibitor, Chidamide, Exerts Dual Anti-Myeloma and Bone Protective Effect in Vitro and In Vivo

Jingsong He, MD, Qingxiao Chen, MS, Yang Yang, MD, Yi Li, MD, Li Yang, MD, He Huang, MD PhD, Qing Yi, MD PhD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 5392.

https://doi.org/10.1182/blood.V130.Suppl_1.5392.5392

Published: 2017

Journal Articles

Outcome of Acute Myeloid Leukemia Patients with Abnormal 12p after Allogeneic Hematopoietic Cell Transplantation at Fred Hutchinson Cancer Research Center

Eric Konnick, MD, Yi Li, MD, Emily Silgard, MS, Chris Davis, Ted Gooley, PhD, Frederick R. Appelbaum, MD, Lue Ping Zhao, PhD, Min Fang, MDPhD

Blood (2017) 130 (Supplement 1): 1396.

https://doi.org/10.1182/blood.V130.Suppl_1.1396.1396

Published: 2017

Journal Articles

Pro-Inflammatory Cytokine IL-1b on Megakaryopoiesis: A Possible Explanation of Thrombocytosis in Inflammation

Mo Yang, MD PhD, Su-yi Li, MD, Xin Zhang, Rui Cao, Chunfu Li, MD, Beng H Chong, MBBS, PhD

Blood (2017) 130 (Supplement 1): 4851.

https://doi.org/10.1182/blood.V130.Suppl_1.4851.4851

Published: 2017

NARROW

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Population Pharmacokinetics/Pharmacodynamics and Clinical Pharmacology of Zaltenibart (OMS906) in Healthy Subjects and Patients with PNH

Selinexor Combined with Daratumumab, Thalidomide, and Dexamethasone in Patients with First Relapsed Multiple Myeloma: A Single-Arm, Multicenter, Prospective Study

Bruton's Tyrosine Kinase (BTK) Inhibitors Plus RM (rituximab and methotrexate) for the First-Line Treatment of Primary Central Nervous System Lymphoma (PCNSL)

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study

Increase of Dnts Correlated with Clinic Outcome after Allogeneic DNT Cells Infusion in r/r AML Patients

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

A Prospective Phase II Clinical Study of Low-Frequency Daratumumab for the Treatment of Systemic Light Chain Amyloidosis

Alternative Pathway Masp-3 Inhibitor OMS906 Effectively and Potently Inhibits Complement-Mediated Hemolysis in Preclinical Models Mechanistically Similar to Paroxysmal Nocturnal Hemoglobinuria

The Efficacy of Roxadustat in Multiple Myeloma Patients with Renal Insufficiency and Anemia: A Real-World Study

Real-World Clinical Outcomes of Pomalidomide-Based and Daratumumab-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Cohort Study

Serum Ferritin Increased the Predictive Value of the International Staging System/Revised International Staging System for Overall Survival

Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma

ALKBH5 Functions As an Oncogene in Multiple Myeloma

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

CCL2 Promotes Macrophages-Associated Chemoresistance Via MCPIP1 Dual Catalytic Activities in Multiple Myeloma

The Novel Subtype-Selective Histone Deacetylase (HDAC) Inhibitor, Chidamide, Exerts Dual Anti-Myeloma and Bone Protective Effect in Vitro and In Vivo

Outcome of Acute Myeloid Leukemia Patients with Abnormal 12p after Allogeneic Hematopoietic Cell Transplantation at Fred Hutchinson Cancer Research Center

Pro-Inflammatory Cytokine IL-1b on Megakaryopoiesis: A Possible Explanation of Thrombocytosis in Inflammation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only